Compare Merck & Co., Inc. (MRK) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Synchrony Financial — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Synchrony Financial trades at $71.7 (market cap $24.69B). The key difference: Merck & Co., Inc. is far larger — about 12.4× Synchrony Financial's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | SYF | |
|---|---|---|
Market Cap | $307.25B | $24.69B |
Sector | Health | Financials |
52-Week High | $129.52 | $88.47 |
52-Week Low | $77.60 | $63.78 |
Enterprise Value | $350.66B | — |
Dividend Yield | 2.73% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Synchrony Financial (SYF) trades at $73.41, down 0.29% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a net income margin of 24.06% and ROE of 22.98%, supported by consistent earnings beats in recent quarters. Recent Q2 2026 results highlighted record purchase volume and a raised EPS outlook, though cash flow trends indicate a net outflow projection for 2026. Analyst consensus remains strongly bullish with a $86.38 price target.
The outlook for SYF is positive based on fundamental strength and analyst confidence, but near-term technical pressure and macroeconomic sensitivity pose risks. Investment appeal lies in its low P/E of 7.6 and dividend yield, though investors should monitor credit quality and interest rate impacts given its consumer lending focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
